Understand the source comparison
Cagrilintide vs Ozempic Comparison: Research Applications
Primary Receptor Target Amylin receptor (CTR/RAMP complex) GLP-1 receptor Distinct pathways. Combination shows additive effect Approved Indication None (Phase II/III) Type 2 diabetes Obesity (BMI ≥30 or ≥27 with comorbidity) Semaglutide has regulatory approval
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Receptor Target
- Amylin receptor (CTR/RAMP complex)
- GLP-1 receptor
- Distinct pathways. Combination shows additive effect
- Approved Indication
- None (Phase II/III)
- Type 2 diabetes
- Obesity (BMI ≥30 or ≥27 with comorbidity)
- Semaglutide has regulatory approval; cagrilintide in development
- Mean Weight Loss (32 weeks)
- 10.8% at 4.5mg weekly
- ~12% at 1.0mg weekly
- ~12% at 2.4mg weekly
- Comparable efficacy at matched timepoints
- Mean Weight Loss (68 weeks)
- Data pending Phase III
- 9–11% at 1.0mg
- 14.9% at 2.4mg
- Longer-duration data favors semaglutide currently
- Nausea Incidence
- 52% during titration (4.5mg dose)
- 20–30% during titration (1.0mg dose)
- 44% during titration (2.4mg dose)
- Higher with cagrilintide but resolves more completely post-titration
- Discontinuation Rate (AE)
- 8% (Phase II data)
- 3–4% (SUSTAIN trials)
- 6.8% (STEP-1)
- Lower discontinuation with semaglutide
- Half-Life
- ~7 days
- Weekly dosing viable for both
- Glucagon Suppression
- Direct and pronounced
- Indirect via insulin/GLP-1 axis
- Cagrilintide shows stronger post-meal glucagon blunting
- A1C Reduction
- Data pending
- 1.5–1.8%
- 1.2–1.5% (secondary endpoint)
- Semaglutide demonstrates robust glycemic control